| Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells JJ García-Vallejo, M Ambrosini, A Overbeek, WE van Riel, K Bloem, ... Molecular immunology 53 (4), 387-397, 2013 | 121 | 2013 |
| Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients K Bloem, A van Leeuwen, G Verbeek, MT Nurmohamed, GJ Wolbink, ... Journal of immunological methods 418, 29-38, 2015 | 88 | 2015 |
| Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study N Wilkinson, T Tsakok, N Dand, K Bloem, M Duckworth, D Baudry, ... Journal of Investigative Dermatology 139 (1), 115-123, 2019 | 69 | 2019 |
| Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context K Bloem, B Hernández-Breijo, A Martínez-Feito, T Rispens Therapeutic drug monitoring 39 (4), 327-332, 2017 | 65 | 2017 |
| BODIPY-labeled DC-SIGN-targeting glycodendrons efficiently internalize and route to lysosomes in human dendritic cells R Ribeiro-Viana, JJ Garcia-Vallejo, D Collado, E Perez-Inestrosa, ... Biomacromolecules 13 (10), 3209-3219, 2012 | 60 | 2012 |
| Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain K Bloem, IM Vuist, AJ van der Plas, LMJ Knippels, J Garssen, ... PLoS One 8 (6), e66266, 2013 | 56 | 2013 |
| DCIR interacts with ligands from both endogenous and pathogenic origin K Bloem, IM Vuist, M van den Berk, EJ Klaver, I van Die, LMJ Knippels, ... Immunology letters 158 (1-2), 33-41, 2014 | 54 | 2014 |
| Identification and characterization of a complete carnitine biosynthesis pathway in Candida albicans K Strijbis, CWT Van Roermund, GP Hardy, J Van den Burg, K Bloem, ... The FASEB Journal 23 (8), 2349-2359, 2009 | 48 | 2009 |
| Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot K Bloem, T Schaap, R Boshuizen, EL Kneepkens, GJ Wolbink, A Vries, ... Bioanalysis 10 (11), 815-823, 2018 | 45 | 2018 |
| Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay LC Berkhout, MJ l’Ami, J Ruwaard, MH Hart, PO Heer, K Bloem, ... Science Translational Medicine 11 (477), eaat3356, 2019 | 42 | 2019 |
| The consequences of multiple simultaneous C-type lectin–ligand interactions: DCIR alters the endo-lysosomal routing of DC-SIGN JJ García-Vallejo, K Bloem, LMJ Knippels, J Garssen, SJ van Vliet, ... Frontiers in Immunology 6, 132847, 2015 | 40 | 2015 |
| Association of serum ustekinumab levels with clinical response in psoriasis T Tsakok, N Wilson, N Dand, FC Loeff, K Bloem, D Baudry, M Duckworth, ... JAMA dermatology 155 (11), 1235-1243, 2019 | 39 | 2019 |
| Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti‐adalimumab in patients with inflammatory diseases EL Kneepkens, MF Pouw, GJ Wolbink, T Schaap, MT Nurmohamed, ... British journal of clinical pharmacology 83 (11), 2474-2484, 2017 | 37 | 2017 |
| Interaction of the Capsular Polysaccharide A from Bacteroides fragilis with DC-SIGN on Human Dendritic Cells is Necessary for Its Processing and Presentation to … K Bloem, JJ García-Vallejo, IM Vuist, BA Cobb, SJ van Vliet, Y Van Kooyk Frontiers in immunology 4, 103, 2013 | 37 | 2013 |
| Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: a clinical validation SE Berends, GRAM D'Haens, T Schaap, A de Vries, T Rispens, K Bloem, ... British journal of clinical pharmacology 85 (7), 1544-1551, 2019 | 32 | 2019 |
| Toll-like receptor 4 triggering promotes cytosolic routing of DC-SIGN-targeted antigens for presentation on MHC class I SK Horrevorts, S Duinkerken, K Bloem, P Secades, H Kalay, RJ Musters, ... Frontiers in immunology 9, 1231, 2018 | 32 | 2018 |
| Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients T Jurado, C Plasencia-Rodríguez, A Martínez-Feito, V Navarro-Compán, ... The Open Rheumatology Journal 11, 75, 2017 | 24 | 2017 |
| Monitoring of adalimumab concentrations at home in patients with inflammatory bowel disease using dried blood samples SE Berends, K Bloem, A de Vries, T Schaap, T Rispens, AS Strik, ... Therapeutic drug monitoring 42 (2), 289-294, 2020 | 16 | 2020 |
| Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial J Jacobse, W Ten Voorde, A Tandon, SG Romeijn, HW Grievink, ... British journal of clinical pharmacology 87 (8), 3162-3176, 2021 | 11 | 2021 |
| Using real‐world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic‐pharmacodynamic study S Pan, T Tsakok, N Dand, DO Lonsdale, FC Loeff, K Bloem, A de Vries, ... Clinical and Translational Science 13 (2), 400-409, 2020 | 10 | 2020 |
